6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

Summary Deletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of patients. Its effect on patient outcome has not been completely established. We used fluorescence in situ hybridisation to a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2021-03, Vol.192 (5), p.843-852
Hauptverfasser: García‐Sanz, Ramón, Dogliotti, Irene, Zaccaria, Gian Maria, Ocio, Enrique María, Rubio, Araceli, Murillo, Ilda, Escalante, Fernando, Aguilera, Carmen, García‐Mateo, Aránzazu, García de Coca, Alfonso, Hernández, Roberto, Dávila, Julio, Puig, Noemí, García‐Álvarez, María, Chillón, María del Carmen, Alcoceba, Miguel, Medina, Alejandro, González de la Calle, Verónica, Sarasquete, María Eugenia, González, Marcos, Gutiérrez, Norma Carmen, Jiménez, Cristina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Deletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of patients. Its effect on patient outcome has not been completely established. We used fluorescence in situ hybridisation to analyse the prevalence of del6q in selected CD19+ bone marrow cells of 225 patients with newly diagnosed immunoglobulin M (IgM) monoclonal gammopathies. Del6q was identified in one of 27 (4%) cases of IgM‐monoclonal gammopathy of undetermined significance, nine of 105 (9%) of asymptomatic WM (aWM), and 28/93 (30%) of symptomatic WM (sWM), and was associated with adverse prognostic features and higher International Prognostic Scoring System for WM (IPSSWM) score. Asymptomatic patients with del6q ultimately required therapy more often and had a shorter time to transformation (TT) to symptomatic disease (median TT, 30 months vs. 199 months, respectively, P 
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17028